09:44 AM EST - Oncolytics Biotech Inc : Today announced recent operational highlights and financial results for the fourth quarter and full year ended December 31, 2022. Highlights include The Pancreatic cancer program advancing towards registration path supported by phase 1/2 GOBLET data showing a confirmed complete response and 69% objective response rate in advanced/metastatic patients; Phase 2 BRACELET-1 trial in HR+/HER2- metastatic breast cancer on track for a randomized data readout in Q2 2023 that will inform the design of a pivotal trial; $32.1 million in cash, cash equivalents and marketable securities as of December 31, 2022 provides projected runway through BRACELET-1's upcoming readout and into 2024. Oncolytics Biotech Inc
shares T.ONC are trading -$0.06 at $2.20.
Full Press Release: https://www.baystreet.ca/quotedata/quote.aspx?ticker=ONC%3ACA&qmodStoryID=6863947012847754
